Rilematovir
Rilematovir (JNJ-678) is a novel fusion protein inhibitor. Rilematovir has the potential for respiratory syncytial virus (RSV) research.
Product Specifications
CAS Number
[1383450-81-4]
Product Name Alternative
JNJ-678; JNJ-53718678
UNSPSC
12352005
Hazard Statement
H315, H319, H320
Target
RSV
Type
Reference compound
Related Pathways
Anti-infection
Applications
COVID-19-anti-virus
Field of Research
Infection
Assay Protocol
https://www.medchemexpress.com/JNJ-53718678.html
Purity
98.0
Solubility
DMSO : 65 mg/mL (ultrasonic)
Smiles
O=C(N1CC(F)(F)F)N(CC(N2CCCS(=O)(C)=O)=CC3=C2C=CC(Cl)=C3)C4=C1C=CN=C4
Molecular Formula
C21H20ClF3N4O3S
Molecular Weight
500.92
Precautions
H315, H319, H320
References & Citations
[1]Roymans D, et al. Therapeutic efficacy of a respiratory syncytial virus fusion inhibitor. Nat Commun. 2017 Aug 1;8 (1) :167.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 3
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
040358-ML405 100 µL
PPP3CA, CT (PPP3CA, CALNA, CNA, Serine/threonine-protein phosphatase 2B catalytic subunit alpha isoform, CAM-PRP catalytic subunit, Calmodulin-dependent calcineurin A subunit alpha isoform) (MaxLight 405) discontinued
Ask
View Details